Tissue-type plasminogen activator precursor
Tissue-type plasminogen activator precursor Brand names, Tissue-type plasminogen activator precursor Analogs
Tissue-type plasminogen activator precursor Brand Names Mixture
- No information avaliable
Tissue-type plasminogen activator precursor Chemical_Formula
C1736H2671N499O522S22
Tissue-type plasminogen activator precursor RX_link
http://www.rxlist.com/cgi/generic2/reteplase.htm
Tissue-type plasminogen activator precursor fda sheet
Tissue-type plasminogen activator precursor msds (material safety sheet)
Tissue-type plasminogen activator precursor Synthesis Reference
No information avaliable
Tissue-type plasminogen activator precursor Molecular Weight
39589.6
Tissue-type plasminogen activator precursor Melting Point
60 oC (Novokhatny, V.V. et al., J. Biol. Chem. 266:12994-123002 (1991))
Tissue-type plasminogen activator precursor H2O Solubility
No information avaliable
Tissue-type plasminogen activator precursor State
Liquid
Tissue-type plasminogen activator precursor LogP
-0.435
Tissue-type plasminogen activator precursor Dosage Forms
Solution (IV injection); Powder for solution
Tissue-type plasminogen activator precursor Indication
For lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
Tissue-type plasminogen activator precursor Pharmacology
Retavase cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.
Tissue-type plasminogen activator precursor Absorption
No information avaliable
Tissue-type plasminogen activator precursor side effects and Toxicity
No information avaliable
Tissue-type plasminogen activator precursor Patient Information
No information avaliable
Tissue-type plasminogen activator precursor Organisms Affected
Humans and other mammals
